Open Observation and Control Study of the Efficacy and Safety of Paliperidone Extended-release Tablets and Risperidone Tablets in the Treatment of First-episode Schizophrenia

Objective To evaluate the efficacy and safety of paliperidone extended-release tablets and risperidone tablets in the treatment of first-episode schizophrenia. Methods 56 cases of first-episode schizophrenia patients were selected as the subjects and divided into study group and the control group with 28 cases in each, and the two groups were given paliperidone extendedrelease tablets and risperidone tablets treatment, respectively. Positive and Negative Syndrome Scale(PANSS) was used to assess the efficacy before the treatment and at 1, 2, 4, 8 weeks after the treatment; Treatment Emergent Symptom Scale(TESS) was used to evaluate the adverse reactions. Results After treatment, the PANSS total scores and factor scores of both groups of patients were lower than those before treatment, the differences were statistically significant(P0.01);the PANSS total score 2 weeks after the treatment and the PANSS negative score 2,4,8 weeks after the treatment of the study group were lower than those of the control group, the differences were statistically significant(P0.01); the clinical total effective rate 8 weeks after the treatment of the two groups was 78.6%, 71.4%, respectively, the difference was not statistically significant(P0.05); the difference in incidence of adverse reactions between two groups was statistically significant(P0.05). Conclusion The effect of paliperidone extended-release tablets for the treatment of schizophrenia disease is definite, and it is better than risperidone especially in taking effect early and improving negative symptoms with better safety.